Bayer AG Stock Gains Traction as Analyst Upgrades and US Legal Progress Signal Potential Turnaround

Bayer AG stock (ISIN: DE000BAY0017) draws fresh investor interest amid analyst upgrades from Oddo BHF, Goldman Sachs and UBS, coupled with a Kansas bill targeting glyphosate lawsuits and a key US Supreme Court date on April 27. DACH investors eye restructuring progress and pipeline wins in pharma.

Bayer AG stock is experiencing renewed optimism as analysts upgrade ratings and US legal developments offer relief from glyphosate litigation woes. Shares on Xetra closed Friday at €37.65, down 1.59% but showing technically oversold signals with an RSI of 20.1. For DACH investors, this confluence of factors highlights a potential bottoming process in a Leverkusen giant long burdened by Monsanto legacy issues.

As of: 22.03.2026

By Dr. Elena Voss, Senior Pharma and Agri-Chem Analyst. Tracking Bayer's dual-track recovery in pharmaceuticals and crop science amid litigation headwinds and strategic pivots.

Analyst Upgrades Reflect Shifting Sentiment

Wall Street and European banks are raising their sights on Bayer AG stock. Oddo BHF upgraded to 'Outperform' with a €55.00 target, up from €39.80. Goldman Sachs initiated coverage at €54.00, while UBS moved to 'Buy' with €52.00 and Barclays held 'Overweight' at €48.00.

These revisions stem from CEO Bill Anderson's restructuring momentum. Short interest dropped nearly 50% by late February, signaling reduced bearish bets. On Xetra, Bayer AG stock trades at a discount to these targets, with the 50-day moving average at €42.80.

The upgrades coincide with technical oversold conditions. Bayer AG stock's RSI hit 20.1 on a 14-day basis, often a contrarian buy signal. Investors await the April 24 annual general meeting for dividend and board votes.

US Legal Tailwinds Build Momentum

A Kansas bill could shield Bayer from future glyphosate suits by limiting liability for federally approved products. This targets failure-to-warn claims post-regulatory clearance, potentially modeling for other states.

More critically, a $7.25 billion Roundup settlement gained preliminary US court approval in early March. The US Supreme Court hears Monsanto v. Durnell on April 27, with a ruling by late June possibly preempting state claims on 65,000 pending cases.

These steps ease a multi-billion overhang. Bayer AG stock on Xetra reflects this, stabilizing after a 17% monthly drop. DACH investors, familiar with Bayer's German roots, see litigation resolution as key to balance sheet relief.

Pharma Pipeline Delivers Growth Catalysts

Bayer's pharmaceuticals shine amid challenges. Kerendia, for kidney disease, posted Phase III success in non-diabetic patients, expanding to a market with $2.6 billion peak sales potential.

Nubeqa, the cancer drug, shows strong growth trajectory. These assets counterbalance crop science pressures, bolstering core earnings.

In 2025, adjusted EBITDA reached €9.67 billion. For 2026, guidance calls for €9.6-10.1 billion currency-adjusted, with stable revenues. Bayer AG stock on Xetra benefits from this operational resilience.

Consumer Health Provides Defensive Anchor

The Consumer Health division, featuring Aspirin and Bepanthen, generated €5.8 billion in 2025 sales. Analysts eye a potential spin-off to unlock value, as noted by Oddo BHF.

This OTC powerhouse offers stability. Aspirin Complex maintains market leadership, with 3-5% annual growth forecasts. For DACH investors, it represents reliable cash flow amid volatility elsewhere.

Bayer's full-year net loss hit €3.62 billion due to settlements, but core operations hold firm. Net debt fell to €29.8 billion.

Restructuring Targets Balance Sheet Relief

CEO Anderson's 'Dynamic Shared Ownership' model aims for €2 billion in savings by 2026 end. This counters negative free cash flow of up to €2.5 billion from €5 billion Roundup payouts.

2026 goals include sales of €44-46 billion, EBITDA before specials €9.1-9.6 billion, core EPS €4.00-4.50, and net debt €32-33 billion. Progress here is pivotal for Bayer AG stock re-rating.

Q1 results on May 12 will test execution. The April 24 AGM features a €0.11 dividend proposal, appealing to income-focused DACH holders despite low yield.

Why DACH Investors Should Watch Closely

As a DACH blue-chip, Bayer AG resonates locally. Leverkusen headquarters ensure regulatory proximity, with 100% free float and market cap near €38 billion on Xetra.

Dividend tradition and defensive OTC streams suit conservative portfolios. Legal wins could boost multiples, while pharma growth taps European healthcare demand. Bayer AG stock offers value at current oversold levels for patient capital.

Germany, Austria, and Switzerland investors benefit from Xetra liquidity and Bayer's industrial footprint. Track Supreme Court outcome for litigation clarity.

Key Risks and Open Questions Remain

Cash strain persists through 2026 from settlements. Failure to hit savings targets risks debt creep. Crop science faces pricing and demand headwinds.

Pipeline execution carries trial risks, and generic competition pressures OTC. Bayer AG stock on Xetra could retest lows if catalysts disappoint. Supreme Court ruling introduces binary outcome.

Macro factors like interest rates impact debt servicing. Investors balance upgrades against near-term negativity.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.